Table 1.
Patient demographics and baseline clinical characteristics.
| Treatment group | ||||||
|---|---|---|---|---|---|---|
| 2 mg N = 14 | 5 mg N = 10 | 10 mg N = 20 | 25 mg N = 15 | Placebo N = 20 | Total N = 79 | |
| Age, years, mean (SD) | 35.8 (7.9) | 37.3 (6.2) | 40.0 (7.1) | 36.9 (7.2) | 38.2 (7.1) | 37.8 (7.1) |
| 18–40 years, n (%) | 10 (71.4) | 7 (70.0) | 10 (50.0) | 9 (60.0) | 12 (60.0) | 48 (60.8) |
| 41–50 years, n (%) | 4 (28.6) | 3 (30.0) | 10 (50.0) | 6 (40.0) | 8 (40.0) | 31 (39.2) |
| Male, n (%) | 11 (78.6) | 7 (70.0) | 18 (90.0) | 11 (73.3) | 14 (70.0) | 61 (77.2) |
| Race, n (%) | ||||||
| Black or African American | 2 (14.3) | 3 (30.0) | 8 (40.0) | 6 (40.0) | 7 (35.0) | 26 (32.9) |
| White | 11 (78.6) | 7 (70.0) | 11 (55.0) | 9 (60.0) | 13 (65.0) | 51 (64.6) |
| Multiple race | 1 (7.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.3) |
| Region, n (%) | ||||||
| North America | 8 (57.1) | 5 (50.0) | 11 (55.0) | 7 (46.7) | 8 (40.0) | 39 (49.4) |
| Europe | 6 (42.9) | 5 (50.0) | 9 (45.0) | 8 (53.3) | 12 (60.0) | 40 (50.6) |
| Baseline clinical scores, mean (SD) | ||||||
| MCCB overall composite T-score | 27.5 (11.2) | 37.2 (9.3) | 28.1 (10.6) | 27.4 (15.6) | 33.3 (10.3) | 30.3 (11.8) |
| MCCB neurocognitive T-score | 29.0 (11.5) | 37.5 (8.5) | 30.3 (9.8) | 29.1 (16.3) | 33.4 (9.4) | 31.5 (11.5) |
| PANSS total score | 65.6 (16.0) | 57.9 (16.1) | 63.7 (19.3) | 55.2 (16.3) | 57.6 (19.9) | 60.1 (18.0) |
| PANSS negative subscale | 18.0 (4.7) | 15.7 (5.5) | 18.2 (6.4) | 14.7 (4.3) | 15.3 (5.0) | 16.4 (5.4) |
| PANSS positive subscale | 14.7 (6.1) | 13.7 (6.2) | 14.1 (5.8) | 13.7 (6.0) | 13.2 (6.3) | 13.9 (5.9) |
| Concomitant antipsychotic therapy, n % | 14 (100.0) | 10 (100.0) | 19 (95.0) | 15 (100.0) | 20 (100.0) | 78 (98.7) |
MATRICS Measurement and Treatment Research to Improve Cognition in Schizophrenia; MCCB MATRICS Consensus Cognitive Battery; PANSS Positive and Negative Syndrome Scale; SD standard deviation.